Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Published Erratum
. 2025 Aug 12;12(2):62-66.
doi: 10.36469/001c.143106. eCollection 2025.

Correction: Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US

Niodita Gupta-Werner  1 , Vipin Khare  1 , Brian Macomson  1 , Rohan Medhekar  1
Affiliations
Published Erratum

Correction: Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US

Niodita Gupta-Werner et al. J Health Econ Outcomes Res. .

Abstract

[This corrects the article DOI: 10.36469/001c.141714.].

Keywords: cost analysis; daratumumab; isatuximab; multiple myeloma; wholesale acquisition cost.

PubMed Disclaimer

Erratum for

Similar articles

See all similar articles

References

    1. The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Huang J., Chan S.C., Lok V.., et al. 2022Lancet Haematol. 9(9):e670–e677. doi: 10.1016/S2352-3026(22)00165-X. - DOI - PubMed
    1. Value and cost of myeloma therapy. Rajkumar S.V. 2018Am Soc Clin Oncol Educ Book. 38:662–666. doi: 10.1200/EDBK_200867. - DOI - PubMed
    1. Current approaches to management of newly diagnosed multiple myeloma. Goel U., Usmani S., Kumar S. 2022Am J Hematol. 97(suppl 1):S3–S25. - PubMed
    1. Transplant eligibility in elderly multiple myeloma patients: prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. Belotti A., Ribolla R., Cancelli V.., et al. 2020Am J Hematol. 95(7):759–765. doi: 10.1002/ajh.25797. - DOI - PubMed
    1. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. Facon T., Dimopoulos M. A., Leleu X. P.., et al. 2024N Engl J Med. 391(17):1597–1607. doi: 10.1056/NEJMoa2400712. - DOI - PubMed

Publication types

LinkOut - more resources